These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 28882110)

  • 1. Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function.
    Collado S; Coll E; Nicolau C; Azqueta M; Pons M; Cruzado JM; de la Torre B; Deulofeu R; Mojal S; Pascual J; Cases A
    BMC Nephrol; 2017 Sep; 18(1):290. PubMed ID: 28882110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers of vascular calcification and mortality in patients with ESRD.
    Scialla JJ; Kao WH; Crainiceanu C; Sozio SM; Oberai PC; Shafi T; Coresh J; Powe NR; Plantinga LC; Jaar BG; Parekh RS
    Clin J Am Soc Nephrol; 2014 Apr; 9(4):745-55. PubMed ID: 24458076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease.
    Winther S; Christensen JH; Flyvbjerg A; Schmidt EB; Jørgensen KA; Skou-Jørgensen H; Svensson M
    Clin Nephrol; 2013 Sep; 80(3):161-7. PubMed ID: 23547804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain natriuretic peptide between traditional and nontraditional risk factors in hemodialysis patients: analysis of cardiovascular mortality in a two-year follow-up.
    Selim G; Stojceva-Taneva O; Spasovski G; Georgievska-Ismail L; Zafirovska-Ivanovska B; Gelev S; Dzekova P; Trajcevska L; Trojacanec-Piponska S; Sikole A
    Nephron Clin Pract; 2011; 119(2):c162-70. PubMed ID: 21757955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum osteoprotegerin is associated with vascular stiffness and the onset of new cardiovascular events in hemodialysis patients.
    Lee JE; Kim HJ; Moon SJ; Nam JS; Kim JK; Kim SK; Yun GY; Ha SK; Park HC
    Korean J Intern Med; 2013 Nov; 28(6):668-77. PubMed ID: 24307842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated Circulating Osteoprotegerin Levels in the Plasma of Hemodialyzed Patients With Severe Artery Calcification.
    Krzanowski M; Krzanowska K; Dumnicka P; Gajda M; Woziwodzka K; Fedak D; Grodzicki T; Litwin JA; Sułowicz W
    Ther Apher Dial; 2018 Oct; 22(5):519-529. PubMed ID: 29974642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients.
    Pateinakis P; Papagianni A; Douma S; Efstratiadis G; Memmos D
    BMC Nephrol; 2013 Jun; 14():122. PubMed ID: 23758931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated osteoprotegerin levels predict cardiovascular events in new hemodialysis patients.
    Nishiura R; Fujimoto S; Sato Y; Yamada K; Hisanaga S; Hara S; Nakao H; Kitamura K
    Am J Nephrol; 2009; 29(3):257-63. PubMed ID: 18802328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study.
    Svensson M; Dahle DO; Mjøen G; Weihrauch G; Scharnagl H; Dobnig H; März W; Jardine A; Fellström B; Holdaas H
    Nephrol Dial Transplant; 2012 Jun; 27(6):2571-5. PubMed ID: 22172725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ratio of osteoprotegerin to fetuin-a is independently associated with vascular stiffness in hemodialysis patients.
    Kim HR; Kim SH; Han MJ; Yoon YS; Oh DJ
    Nephron Clin Pract; 2013; 123(3-4):165-72. PubMed ID: 23921088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients.
    Nakashima A; Carrero JJ; Qureshi AR; Hirai T; Takasugi N; Ueno T; Taniguchi Y; Lindholm B; Yorioka N
    Osteoporos Int; 2011 Jun; 22(6):1695-701. PubMed ID: 20812007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated osteoprotegerin is associated with inflammation, malnutrition and new onset cardiovascular events in peritoneal dialysis patients.
    Koo HM; Do HM; Kim EJ; Lee MJ; Shin DH; Kim SJ; Oh HJ; Yoo DE; Kim JK; Park JT; Han SH; Kang SW; Choi KH; Yoo TH
    Atherosclerosis; 2011 Dec; 219(2):925-30. PubMed ID: 22015178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fetuin A/nutritional status predicts cardiovascular outcomes and survival in hemodialysis patients.
    Chen HY; Chiu YL; Hsu SP; Pai MF; Yang JY; Peng YS
    Am J Nephrol; 2014; 40(3):233-41. PubMed ID: 25322785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum osteoprotegerin is an independent marker of central arterial stiffness as assessed using carotid-femoral pulse wave velocity in hemodialysis patients: a cross sectional study.
    Hou JS; Lin YL; Wang CH; Lai YH; Kuo CH; Subeq YM; Hsu BG
    BMC Nephrol; 2019 May; 20(1):184. PubMed ID: 31122190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3-5.
    Marques GL; Hayashi S; Bjällmark A; Larsson M; Riella M; Olandoski M; Lindholm B; Nascimento MM
    Sci Rep; 2021 Jan; 11(1):2473. PubMed ID: 33510348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum fetuin a in hemodialysis: a link between derangement of calcium-phosphorus homeostasis and progression of atherosclerosis?
    Pertosa G; Simone S; Ciccone M; Porreca S; Zaza G; Dalfino G; Memoli B; Procino A; Bonomini M; Sirolli V; Castellano G; Gesualdo L; Ktena M; Schena FP; Grandaliano G
    Am J Kidney Dis; 2009 Mar; 53(3):467-74. PubMed ID: 19167798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease.
    Nascimento MM; Hayashi SY; Riella MC; Lindholm B
    Braz J Med Biol Res; 2014 Nov; 47(11):995-1002. PubMed ID: 25296363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients.
    Hjelmesaeth J; Ueland T; Flyvbjerg A; Bollerslev J; Leivestad T; Jenssen T; Hansen TK; Thiel S; Sagedal S; Røislien J; Hartmann A
    J Am Soc Nephrol; 2006 Jun; 17(6):1746-54. PubMed ID: 16687626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure.
    Kuźniewski M; Fedak D; Dumnicka P; Stępień E; Kuśnierz-Cabala B; Cwynar M; Sułowicz W
    Adv Med Sci; 2016 Sep; 61(2):269-275. PubMed ID: 27128817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease.
    Matsubara K; Stenvinkel P; Qureshi AR; Carrero JJ; Axelsson J; Heimbürger O; Bárány P; Alvestrand A; Lindholm B; Suliman ME
    J Nephrol; 2009; 22(6):774-82. PubMed ID: 19967657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.